Human antibody technology may be hot, but it's not always enough. To round out its capabilities, Abgenix Inc. has been acquiring complementary technologies. Its latest move was last week's purchase of Hesed Biomed Inc., a developer of catalytic antibodies (CAbs). The new technology is expected to be used in situations where the use of conventional MAbs are less favorable.

ABGX (Fremont, Calif.) will acquire Hesed (Omaha, Neb.) for $17.9 million, including $360,000 in cash and 540,000 ABGX shares valued at $17.5 million based on ABGX's Friday close at $32.47.